Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Interpace Biosciences Inc IDXG

Healthcare
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by... see more

Recent & Breaking News (OTCQX:IDXG)

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

GlobeNewswire November 4, 2024

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

GlobeNewswire October 15, 2024

Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

GlobeNewswire August 1, 2024

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

GlobeNewswire July 29, 2024

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

GlobeNewswire June 4, 2024

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results

GlobeNewswire May 9, 2024

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

GlobeNewswire March 7, 2024

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

GlobeNewswire November 8, 2023

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results

GlobeNewswire August 9, 2023

Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement

GlobeNewswire July 10, 2023

Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

GlobeNewswire June 5, 2023

Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results

GlobeNewswire May 12, 2023

Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results

GlobeNewswire March 27, 2023

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

GlobeNewswire November 14, 2022

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

GlobeNewswire October 20, 2022

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

GlobeNewswire September 1, 2022

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

GlobeNewswire August 31, 2022

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

GlobeNewswire August 15, 2022

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

GlobeNewswire May 16, 2022

Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience

GlobeNewswire May 11, 2022